Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure

Annals of Internal Medicine

Volumn 160, Issue 10, 2014, Pages 672-683

  Wong, F Lennie ^a   Bhatia, Smita ^a   Landier, Wendy ^a   Francisco, Liton ^a   Leisenring, Wendy ^b   Hudson, Melissa M ^c   Armstrong, Gregory T ^c   Mertens, Ann ^d   Stovall, Marilyn ^e   Robison, Leslie L ^c   Lyman, Gary H ^f   Lipshultz, Steven E ^g   Armenian, Saro H ^a  

^a Department of Population Sciences City of Hope ^*  (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTION; CANCER DIAGNOSIS; CANCER SURVIVOR; CARDIOVASCULAR RISK; CHILDHOOD CANCER; CHILDREN ONCOLOGY GROUP GUIDELINE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH STATUS; HEART LEFT VENTRICLE FAILURE; HUMAN; INCIDENCE; LIFE EXPECTANCY; LIFE HISTORY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SIMULATION;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTHRACYCLINES; CHILD; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SURVIVORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84901277042     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M13-2498     Document Type: Article

References (58)

1. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94:525-33. [PMID: 18347383]
2. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al; American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiolo. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128:1927-95. [PMID: 24081971]
3. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-15. [PMID: 1997853]
4. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC 2nd, Shaikh SL, Mone SM, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicintreated survivors of childhood cancer. J Clin Oncol. 2002;20:4517-22. [PMID: 12454107]
5. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-36. [PMID: 15837978]
6. Landier W, Bhatia S, Eshelman DA, Forte KJ, Sweeney T, Hester AL, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;22:4979-90. [PMID: 15576413]
7. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al; American College of Cardiology. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-235. [PMID: 16160202]
8. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al; Cardiovascular Disease Task Force of the Children's Oncology Group. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics. 2008;121:e387-96. [PMID: 18187811]
9. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
10. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institutesupported resource for outcome and intervention research. J Clin Oncol. 2009; 27:2308-18. [PMID: 19364948]
11. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229-39. [PMID: 11920786]
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302. [PMID: 2057034]
13. Erbel R, Schweizer P, Krebs W, Meyer J, Effert S. Sensitivity and specificity of two-dimensional echocardiography in detection of impaired left ventricular function. Eur Heart J. 1984;5:477-89. [PMID: 6745290]
14. Naik MM, Diamond GA, Pai T, Soffer A, Siegel RJ. Correspondence of left ventricular ejection fraction determinations from two-dimensional echocardiography, radionuclide angiography and contrast cineangiography. J Am Coll Cardiol. 1995;25:937-42. [PMID: 7884101]
15. Lucariello RJ, Sun Y, Doganay G, Chiaramida SA. Sensitivity and specificity of left ventricular ejection fraction by echocardiographic automated border detection: comparison with radionuclide ventriculography. Clin Cardiol. 1997;20: 943-8. [PMID: 9383588]
16. Habash-Bseiso DE, Rokey R, Berger CJ, Weier AW, Chyou PH. Accuracy of noninvasive ejection fraction measurement in a large community-based clinic. Clin Med Res. 2005;3:75-82. [PMID: 16012124]
17. Gimelli A, Landi P, Marraccini P, Sicari R, Frumento P, L'Abbate A, et al. Left ventricular ejection fraction measurements: accuracy and prognostic implications in a large population of patients with known or suspected ischemic heart disease. Int J Cardiovasc Imaging. 2008;24:793-801. [PMID: 18615270]
18. Rovai D, Morales MA, Di Bella G, Prediletto R, De Nes M, Pingitore A, et al. Echocardiography and the clinical diagnosis of left ventricular dysfunction. Acta Cardiol. 2008;63:507-13. [PMID: 18795590]
19. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004;43:1019-26. [PMID: 15028361]
20. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213-20. [PMID: 20117401]
21. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606. [PMID: 19996459]
22. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42:3191-8. [PMID: 16987655]
23. van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30:1429-37. [PMID: 22473161]
24. Pein F, Sakiroglu O, Dahan M, Lebidois J, Merlet P, Shamsaldin A, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37-44. [PMID: 15162142]
25. Guldner L, Haddy N, Pein F, Diallo I, Shamsaldin A, Dahan M, et al. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer. Radiother Oncol. 2006;81:47-56. [PMID: 16989913]
26. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-43. [PMID: 7760889]
27. Blanco E, Beyene J, Maloney AM, Almeida R, Ethier MC, Winick N, et al. Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-Analysis. Leuk Lymphoma. 2012;53:878-85. [PMID: 22066711]
28. Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673-80. [PMID: 24002505]
29. Centers for Disease Control and Prevention. National Hospital Discharge Survey publications and reports. 2001. Accessed at www.cdc.gov/nchs/nhds/nhds- publications.htm on 15 April 2011.
30. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2328-38. [PMID: 19332714]
31. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867-76. [PMID: 17047217]
32. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-84. [PMID: 10760308]
33. Armenian SH, Sun CL, Shannon T, Mills G, Francisco L, Venkataraman K, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118:6023-9. [PMID: 21976673]
34. Kirsch J, McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ. 2000;9:149-58. [PMID: 10721016]
35. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820-8. [PMID: 14990637]
36. Roberts RA, Abrams H, Sembach MK, Lister JJ, Gans RE, Chisolm TH. Utility measures of health-related quality of life in patients treated for benign paroxysmal positional vertigo. Ear Hear. 2009;30:369-76. [PMID: 19322083]
37. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992;327:685-91. [PMID: 1463530]
38. Centers for Medicare & Medicaid Services Web site. Accessed at www.cms .gov on 10 September 2011.
39. First DataBank. Drug pricing policies. 2010. Accessed at www.fdbhealth.com/policies/drug-pricing-policy on 4 May 2011.
40. U.S. Census Bureau. Statistical Abstract of the United States. 2011. Accessed at www.census.gov/compendia/statab on 10 September 2011.
41. Healthcare Cost and Utilization Project (HCUP). Overview of the Nationwide Inpatient Sample. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
42. U.S. Department of Labor. Bureau of Labor Statistics. National Compensation Survey. 2010. Accessed at www.bls.gov/eci on 1 April 2011.
43. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making. 1994;14:259-65. [PMID: 7934713]
44. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163: 1637-41. [PMID: 12885677]
45. Stinnett AA, Mittleman MA, Weinstein MC, Kuntz KM, Cohen JA, Williams LW, et al. Appendix C: the cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. Oxford, United Kingdom: Oxford Univ Pr; 1996:349-91.
46. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Costeffectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation. 2005;112:3569-76. [PMID: 16330698]
47. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009; 101:946-58. [PMID: 19535780]
48. Armstrong GT, Pan Z, Ness KK, Srivastava D, Robison LL. Temporal trends in cause-specific late mortality among 5-year survivors of childhood cancer. J Clin Oncol. 2010;28:1224-31. [PMID: 20124180]
49. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Betaadrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999;33:916-23. [PMID: 10091816]
50. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819-29. [PMID: 12123328]
51. Kremer LC, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13:503-12. [PMID: 12056699]
52. Paulides M, Kremers A, Stohr W, Bielack S, Jurgens H, Treuner J, et al; German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH). Prospective longitudinal evaluation of doxorubicininduced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer. 2006;46:489-95. [PMID: 16333817]
53. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, et al. Review and meta-Analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112:1980-4. [PMID: 24075281]
54. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706. [PMID: 10204198]
55. Preston DL, Lubin JH, McConney M. EPICURE User's Guide. Seattle: Hirosoft International; 1993.
56. Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, et al. The benefits of early combination treatment of carvedilol and an ACEinhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004;18:57-66. [PMID: 15115904]
57. Cohen E. Would your doctor pay for wasted time? CNN Health. 2011. Accessed at www.cnn.com/2011/HEALTH/06/30/time.worth.money.cohen/index.html on 10 March 2011.
58. Centers for Disease Control and Prevention. National Ambulatory Medical Care Survey. 2010. Accessed at www.cdc.gov/nchs/data/ahcd/namcs-summary/2008- namcs-web-tables.pdf on 11 November 2011.